Study details
Enrolling now
Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
Stanford University
NCT IDNCT05833217ClinicalTrials.gov data as of Apr 2026
Target enrollment
55
Study length
about 2.6 years
Ages
18–80
Locations
2 sites in CA
About this study
Researchers are testing whether adipose tissue contributes to long COVID (PASC) by driving chronic inflammation or serving as a reservoir for the virus. The trial will also determine if obesity and insulin resistance are risk factors for PASC.
Based on ClinicalTrials.gov records.
What participants do
- 1.Steady State Plasma Glucose (SSPG) Test
- 2.Undergo Adipose Tissue Biopsy
Primary goalRate of Inflammatory Gene Expression in Adipose Tissue
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Rate of Inflammatory Gene Expression in Adipose Tissue, Triglyceride/HDL-cholesterol ratio
Procedures
biopsy, diagnostic